ALDEYRA
Updated 17 days ago
131 Hartwell Avenue, Suite 320 Lexington, MA 02421
Aldeyra Therapeutics is a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. Aldeyra's lead investigational drug product candidates are potential first-in-class treatments in development for dry eye disease, allergic conjunctivitis, and proliferative vitreoretinopathy. The company is also developing other product candidates for retinal and systemic inflammatory diseases... An estimated 7% of western society suffers from some form of immune-mediated disease. At Aldeyra, we are building a proprietary pipeline focused on compounds with distinct mechanisms of action that target immune-mediated ocular diseases and select systemic conditions... LEXINGTON, Mass. --(BUSINESS WIRE)--Feb. 6, 2024-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company developing innovative therapies for the treatment of immune-mediated diseases, today announced that Todd..
Also known as: Aldeyra Pharmaceuticals, Inc., Aldeyra Therapeutics, Aldeyra Therapeutics, Inc.